Results 1 to 10 of about 218,137 (296)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma

Chronic Diseases and Translational Medicine, 2019
After two decades of unchanged paradigms, the treatment strategies for advanced urothelial bladder cancer have been revolutionized by emerging programmed death ligand-1 (PD-L1)/programmed death-1 (PD1) inhibition therapy.
Wei-Bo Yu, Jian-Yu Rao
doaj   +3 more sources

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade [PDF]

Immunity, Inflammation and Disease, 2021
Introduction Chronic infections lead to the functional exhaustion of T cells. Exhausted T cells are phenotypically differentiated by the surface expression of the immunoinhibitory receptor, such as programmed death‐1 (PD‐1).
Otgontuya Ganbaatar, Satoru Konnai, Tomohiro Okagawa, Yutaro Nojima, Naoya Maekawa, Yoshiki Ichikawa, Atsushi Kobayashi, Tomoyuki Shibahara, Yojiro Yanagawa, Hidetoshi Higuchi, Yukinari Kato, Yasuhiko Suzuki, Shiro Murata, Kazuhiko Ohashi   +13 more
doaj   +4 more sources

Programmed death-ligand 1 regulates ameloblastoma growth and recurrence [PDF]

International Journal of Oral Science
Tumor cell-intrinsic programmed death-ligand 1 (PD-L1) signals mediate tumor initiation, progression and metastasis, but their effects in ameloblastoma (AM) have not been reported.
Linzhou Zhang, Hao Lin, Jiajie Liang, Xuanhao Liu, Chenxi Zhang, Qiwen Man, Ruifang Li, Yi Zhao, Bing Liu   +8 more
doaj   +2 more sources

Expression and Significance of PD-1, PD-L1 and PD-L2 in T Cell Subsets and Myeloma Cells in Newly Diagnosed Multiple Myeloma Patients

Zhongliu Fangzhi Yanjiu, 2022
Objective To investigate the expression of PD-1 and PD-L1/2 in T cell subsets and myeloma cells in the bone marrow from newly diagnosed multiple myeloma (NDMM) patients and their relation with clinical features.
MA Yinjuan, YANG Ke, YANG Xiaying, BAI Jiaofeng, BAI Hai, WU Tao, FU Lihua, JIANG Junfeng, PAN Yaozhu   +8 more
doaj   +1 more source

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression [PDF]

Journal of Pathology and Translational Medicine, 2017
Background Glucose transporter type 1 (GLUT1) expression is linked to glucose metabolism and tissue hypoxia. A recent study reported that GLUT1 was significantly associated with programmed death ligand 1 (PD-L1) as a therapeutic target in relapsed or ...
Young Wha Koh, Jae-Ho Han, Seong Yong Park, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh   +5 more
doaj   +1 more source

Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors

The Turkish Journal of Pediatrics, 2021
Background. Programmed death 1 (PD-1) is a co-receptor which is located at the surface of cells like natural killer, monocytes, T and B cells. It has two ligands including programmed death ligand-1 (PD-L1) and ligand-2 (PD-L2).
Seher Şener, Aylar Poyraz, Arzu Okur, Faruk Güçlü Pınarlı, Ceyda Karadeniz   +4 more
doaj   +1 more source

Emerging role of the immunotherapy in treatment of breast cancer

SVU - International Journal of Medical Sciences, 2021
Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated ...
Nagwa Abd El-Sadek Ahmed*, Maisa Hashem Mohammed   +1 more
doaj   +1 more source

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors [PDF]

, 2016
PURPOSE: Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses ...
Agar, Nathalie Y. R., Bi, Wenya Linda, Du, Ziming, Dunn, Gavin P, Dunn, Ian F, Fecci, Peter E, Freeman, Gordon J, Greenwald, Noah F, Kaiser, Ursula B, Laws, Edward R, Jr, Mei, Yu, Reardon, David A, Santagata, Sandro, Woodmansee, Whitney W   +13 more
core   +21 more sources

PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients [PDF]

Journal of Pathology and Translational Medicine, 2017
Background Programmed death ligand 1 (PD-L1) in tumor cells is known to promote immune escape of cancer by interacting with programmed cell death 1 (PD-1) in tumor infiltrating immune cells.
Jiheun Han, Yongkil Hong, Youn Soo Lee
doaj   +1 more source

Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients

Indian Journal of Rheumatology, 2022
Background: Programmed cell death 1(PD-1)/programmed cell death ligand 1 (PD-L1) pathway is an immune checkpoint implicated in immune tolerance and involved in the pathogenesis of several autoimmune diseases.
Eman Eissa, Rania Kandil, Nehal El-Ghobashy, Walaa Abdelfattah, Zainab Hammouda, Sara Medhat Gadelsayed, Faten Bayoumi   +6 more
doaj   +1 more source